These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 22985614

  • 41. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK, Stavroulakis G, Papadopoulos DP, Krespi P, Hatzizacharias A, Zilidis A, Tsoukala C, Votteas VE.
    Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
    [Abstract] [Full Text] [Related]

  • 42. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission.
    Erdoğan M, Özbek M, Akbal E, Üreten K.
    Turk J Med Sci; 2019 Oct 24; 49(5):1381-1385. PubMed ID: 31549496
    [Abstract] [Full Text] [Related]

  • 43. Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-Schönlein purpura.
    Besbas N, Erbay A, Saatçi U, Ozdemir S, Bakkaloglu A, Ozen S, Topaloglu R.
    Clin Exp Rheumatol; 1998 Oct 24; 16(1):95-8. PubMed ID: 9543574
    [Abstract] [Full Text] [Related]

  • 44. Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
    Higuchi T, Nakamura T, Kakutani H, Ishii H.
    Biol Pharm Bull; 2009 Feb 24; 32(2):179-85. PubMed ID: 19182372
    [Abstract] [Full Text] [Related]

  • 45. [Regulatory mechanism of fibrinolysis system by thrombin activatable fibrinolysis inhibitor (TAFI)].
    Urano T.
    Nihon Yakurigaku Zasshi; 2000 Nov 24; 116(5):298-303. PubMed ID: 11215380
    [Abstract] [Full Text] [Related]

  • 46. Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism.
    Chadarevian R, Jublanc C, Bruckert E, Giral P, Ankri A, Leenhardt L, Chapman J, Turpin G.
    J Endocrinol Invest; 2005 May 24; 28(5):398-404. PubMed ID: 16075920
    [Abstract] [Full Text] [Related]

  • 47. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma.
    Erem C, Kocak M, Nuhoglu I, Yılmaz M, Ucuncu O.
    Clin Endocrinol (Oxf); 2010 Oct 24; 73(4):502-7. PubMed ID: 20039901
    [Abstract] [Full Text] [Related]

  • 48. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
    Mosnier LO.
    J Biol Chem; 2011 Jan 07; 286(1):502-10. PubMed ID: 21041299
    [Abstract] [Full Text] [Related]

  • 49. Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.
    Ieko M, Yoshida M, Naito S, Nakabayashi T, Kanazawa K, Mizukami K, Mukai M, Atsumi T, Koike T.
    Int J Hematol; 2010 Jun 07; 91(5):776-83. PubMed ID: 20490730
    [Abstract] [Full Text] [Related]

  • 50. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
    Antovic JP, Rafik Hamad R, Antovic A, Blombäck M, Bremme K.
    Thromb Haemost; 2002 Oct 07; 88(4):644-7. PubMed ID: 12362237
    [Abstract] [Full Text] [Related]

  • 51. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
    Güldaş M, Altinkaya SÖ, Nergiz S, Demircan-Sezer S, Yüksel H.
    Gynecol Endocrinol; 2015 Jul 07; 31(7):536-9. PubMed ID: 26220768
    [Abstract] [Full Text] [Related]

  • 52. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R.
    Gynecol Endocrinol; 2009 Feb 07; 25(2):110-6. PubMed ID: 19253106
    [Abstract] [Full Text] [Related]

  • 53. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism.
    Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G.
    J Clin Endocrinol Metab; 2001 Feb 07; 86(2):732-7. PubMed ID: 11158038
    [Abstract] [Full Text] [Related]

  • 54. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients.
    Hryszko T, Malyszko J, Malyszko JS, Brzosko S, Pawlak K, Mysliwiec M.
    Nephrol Dial Transplant; 2001 Aug 07; 16(8):1692-6. PubMed ID: 11477176
    [Abstract] [Full Text] [Related]

  • 55. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria.
    Yano Y, Kitagawa N, Gabazza EC, Morioka K, Urakawa H, Tanaka T, Katsuki A, Araki-Sasaki R, Hori Y, Nakatani K, Taguchi O, Sumida Y, Adachi Y.
    J Clin Endocrinol Metab; 2003 Feb 07; 88(2):736-41. PubMed ID: 12574207
    [Abstract] [Full Text] [Related]

  • 56. Thrombin-activatable fibrinolysis inhibitor.
    Marx PF.
    Curr Med Chem; 2004 Sep 07; 11(17):2335-48. PubMed ID: 15379716
    [Abstract] [Full Text] [Related]

  • 57. Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.
    Fidan E, Kavgaci H, Orem A, Yilmaz M, Yildiz B, Fidan S, Akcan B, Ozdemir F, Aydin F.
    Tumour Biol; 2012 Oct 07; 33(5):1519-25. PubMed ID: 22535370
    [Abstract] [Full Text] [Related]

  • 58. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
    Małyszko J, Tymcio J.
    Pol Arch Med Wewn; 2008 Oct 07; 118(1-2):36-41. PubMed ID: 18405171
    [Abstract] [Full Text] [Related]

  • 59. Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC).
    Wada H, Nobori T, Watanabe R, Shiku H, Sakuragawa N.
    Turk J Haematol; 2002 Jun 05; 19(2):235-7. PubMed ID: 27264764
    [Abstract] [Full Text] [Related]

  • 60. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.
    Broze GJ, Higuchi DA.
    Blood; 1996 Nov 15; 88(10):3815-23. PubMed ID: 8916945
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.